HIV prevention messages have typically targeted uninfected, at-risk individuals and have focused on forestalling the acquisition of HIV. Recently, a shift in the HIV prevention field has recognized the importance of developing intervention strategies for HIV-positive individuals, since each new infection begins with someone who is already HIV-infected. Prior studies show that many HIV-positive individuals are continuing to engage in unsafe risk behaviors and that crack use is significantly associated with these risk behaviors. These data also show that crack use is negatively associated with the use of primary outpatient HIV care. The hospital or inpatient ward may be an important, yet largely untapped setting to provide prevention interventions to high-risk, HIV-positive crack users. Hospitals also provide an important setting for HIV prevention interventions with infected crack users, because hospitalization may serve as a """"""""teachable moment"""""""" when patients are open to behavioral change interventions. Our multi-site study between the University of Miami and Emory University will be conducted at Jackson Memorial Hospital in Miami, Florida and Grady Memorial Hospital in Atlanta, Georgia. We will evaluate the efficacy of a brief, theoretically-guided, """"""""Prevention Care Advocate"""""""" intervention with HIV-positive crack users recruited from the HIV inpatient hospital wards at Jackson and Grady hospitals. We will provide a multicomponent, skills-building intervention that encourages participants to advocate for prevention and receipt of primary care services for themselves and their peers. These intervention strategies are adapted from strategies recently developed and tested in previous CDC-funded multi-site studies. We will employ a randomized experimental design to compare the intervention's efficacy with an attention-control group. Participants will be assessed at baseline and 6 and 12 months after completing the intervention. The primary outcome of the study will be to reduce unprotected sex. Secondary outcomes will include increasing the use of HIV primary outpatient cars and increasing readiness for and entry to drug treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
1R01DA017612-01A2
Application #
6947609
Study Section
Special Emphasis Panel (ZRG1-AARR-G (02))
Program Officer
Jenkins, Richard A
Project Start
2005-06-06
Project End
2010-05-31
Budget Start
2005-06-06
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$590,567
Indirect Cost
Name
University of Miami School of Medicine
Department
Public Health & Prev Medicine
Type
Schools of Medicine
DUNS #
052780918
City
Miami
State
FL
Country
United States
Zip Code
33146
Kenya, Sonjia; Chida, Natasha; Cardenas, Gabriel et al. (2014) Case Management: Steadfast Resource for Addressing Linkage to Care and Prevention with Hospitalized HIV-Infected Crack Users. J HIV AIDS Soc Serv 13:325-326
Rosa-Cunha, Isabella; Hooton, Thomas M; Cardenas, Gabriel A et al. (2014) Human papillomavirus awareness among HIV-infected drug users in two urban areas. Int J STD AIDS 25:992-6
Vogenthaler, Nicholas S; Hadley, Craig; Rodriguez, Allan E et al. (2011) Depressive symptoms and food insufficiency among HIV-infected crack users in Atlanta and Miami. AIDS Behav 15:1520-6
Rosa-Cunha, Isabella; Cardenas, Gabriel A; Dickinson, Gordon et al. (2010) Addressing anal health in the HIV primary care setting: a disappointing reality. AIDS Patient Care STDS 24:533-8
Bell, Christine; Metsch, Lisa R; Vogenthaler, Nicholas et al. (2010) Never in care: characteristics of HIV-infected crack cocaine users in 2 US cities who have never been to outpatient HIV care. J Acquir Immune Defic Syndr 54:376-80
Vogenthaler, Nicholas S; Hadley, Craig; Lewis, Sarah J et al. (2010) Food insufficiency among HIV-infected crack-cocaine users in Atlanta and Miami. Public Health Nutr 13:1478-84
Metsch, Lisa R; Bell, Christine; Pereyra, Margaret et al. (2009) Hospitalized HIV-infected patients in the era of highly active antiretroviral therapy. Am J Public Health 99:1045-9